https://www.selleckchem.com/pr....oducts/Adriamycin.ht
Results The relative risks of all-grade PN and all-grade PSN were lower with T-DM1 compared to taxanes. The pooled RR of all-grade PN was 0.59, 95% CI 0.39-0.89, P = 0.01, and the pooled RR of all-grade PSN was 0.58, 95% CI 0.46-0.74, P less then 0.0001. Conclusions Our meta-analysis demonstrated that T-DM1 is associated with a relatively lower risk of all-grade PN and PSN than the taxane-based regimens for HER2-positive cancers. It could be an area of consideration in selecting therapy for HER2-positive breast cancer patients at hig
Like
Comment
Share
